Los Angeles Capital Management LLC Has $1.55 Million Holdings in Generation Bio Co. (NASDAQ:GBIO)

Los Angeles Capital Management LLC raised its holdings in shares of Generation Bio Co. (NASDAQ:GBIO) by 38.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 381,661 shares of the company’s stock after buying an additional 105,827 shares during the quarter. Los Angeles Capital Management LLC owned about 0.57% of Generation Bio worth $1,553,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of GBIO. Panagora Asset Management Inc. acquired a new position in shares of Generation Bio during the fourth quarter worth approximately $49,000. Kestra Private Wealth Services LLC bought a new stake in shares of Generation Bio during the fourth quarter valued at approximately $50,000. SG Americas Securities LLC increased its position in shares of Generation Bio by 260.9% during the fourth quarter. SG Americas Securities LLC now owns 48,470 shares of the company’s stock valued at $80,000 after purchasing an additional 35,040 shares during the period. Finally, Weiss Asset Management LP bought a new stake in shares of Generation Bio during the fourth quarter valued at approximately $135,000. 95.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on GBIO shares. Needham & Company LLC restated a “buy” rating and set a $10.00 price objective on shares of Generation Bio in a research report on Tuesday, May 14th. Wedbush restated an “outperform” rating and set a $5.00 price objective on shares of Generation Bio in a research report on Tuesday, May 14th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.00.

Generation Bio Price Performance

Shares of NASDAQ:GBIO opened at $2.75 on Friday. The business’s fifty day moving average price is $3.12 and its two-hundred day moving average price is $2.68. Generation Bio Co. has a fifty-two week low of $0.86 and a fifty-two week high of $6.98. The stock has a market capitalization of $182.95 million, a price-to-earnings ratio of -1.08 and a beta of 2.87.

Generation Bio (NASDAQ:GBIO) last announced its quarterly earnings results on Monday, May 13th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.76). Generation Bio had a negative net margin of 1,696.87% and a negative return on equity of 82.33%. The company had revenue of $4.06 million during the quarter, compared to the consensus estimate of $3.02 million. Research analysts expect that Generation Bio Co. will post -1.68 EPS for the current fiscal year.

Generation Bio Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.